Human tumor infiltrating lymphocytes cooperatively regulate prostate tumor growth in a humanized mouse model

Journal for ImmunoTherapy of Cancer

Volumn 3, Issue 1, 2015, Pages

  Roth, Michael D ^a   Harui, Airi ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Human prostate cancer; Humanized; NOD SCID IL 2R null; Tumor infiltrating lymphocyte

Indexed keywords

CD14 ANTIGEN; CD4 ANTIGEN; CHEMOKINE; CYTOKINE; HLA ANTIGEN CLASS 1; PROSTATE STEM CELL ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GRAFT; CANCER INFILTRATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DENDRITIC CELL; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; HISTOCOMPATIBILITY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LEUKOCYTE; LYMPHOCYTE CULTURE; MONOCYTE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PERIPHERAL LYMPHOCYTE; PHENOTYPE; PRIORITY JOURNAL; PROSTATE TUMOR; SPLEEN CELL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; TUMOR REGRESSION;

EID: 84997764924     PISSN: None     EISSN: 20511426     Source Type: Journal    
DOI: 10.1186/s40425-015-0056-2     Document Type: Article

References (40)

1. Jochems C, Schlom J. Tumor-infiltrating immune cells and prognosis: the potential link between conventional cancer therapy and immunity. Exp Biol Med (Maywood). 2011;236(5):567-79.
2. Vesalainen S, Lipponen P, Talja M, SyrjQnen K. Histological grade, perineural infiltration, tumour-infiltrating lymphocytes and apoptosis as determinants of long-term prognosis in prostatic adenocarcinoma. Eur J Cancer. 1994;30A(12):1797-803.
3. Hinrichs CS, Rosenberg SA. Exploiting the curative potential of adoptive T-cell therapy for cancer. Immunol Rev. 2014;257(1):56-71.
4. Yu P, Steel JC, Zhang M, Morris JC, Waitz R, Fasso M, et al. Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model. Proc Natl Acad Sci U S A. 2012;109(16):6187-92.
5. Zonari E, Pucci F, Saini M, Mazzieri R, Politi LS, Gentner B, et al. A role for miR-155 in enabling tumor-infiltrating innate immune cells to mount effective antitumor responses in mice. Blood. 2013;122(2):243-52.
6. Boissonnas A, Licata F, Poupel L, Jacquelin S, Fetler L, Krumeich S, et al. CD8+ tumor-infiltrating T cells are trapped in the tumor-dendritic cell network. Neoplasia. 2013;15(1):85-94.
7. Ganesan AP, Johansson M, Ruffell B, Yagui-Beltrán A, Lau J, Jablons DM, et al. Tumor-infiltrating regulatory T cells inhibit endogenous cytotoxic T cell responses to lung adenocarcinoma. J Immunol. 2013;191(4):2009-17.
8. + T cells is required for their migration into tumors to elicit effective antitumor immunity. J Immunol. 2013;191(6):3462-70.
9. Reddy S, Piccione D, Takita H, Bankert RB. Human lung tumor growth established in the lung and subcutaneous tissue of mice with severe combined immunodeficiency. Cancer Res. 1987;47(9):2456-60.
10. Williams SS, Chen FA, Kida H, Yokata S, Miya K, Kato M, et al. Engraftment of human tumor-infiltrating lymphocytes and the production of anti-tumor antibodies in SCID mice. J Immunol. 1996;156(5):1908-15.
11. Bankert RB, Egilmez NK, Hess SD. Human-SCID mouse chimeric models for the evaluation of anti-cancer therapies. Trends Immunol. 2001;22(7):386-93.
12. Hess SD, Egilmez NK, Bailey N, Anderson TM, Mathiowitz E, Bernstein SH, et al. Human CD4+ T cells present within the microenvironment of human lung tumors are mobilized by the local and sustained release of IL-12 to kill tumors in situ by indirect effects of IFN-γ. J Immunol. 2003;170(1):400-12.
13. Broderick L, Yokota SJ, Reineke J, Mathiowitz E, Stewart CC, Barcos M, et al. Human CD4+ effector memory T cells persisting in the microenvironment of lung cancer xenografts are activated by local delivery of IL-12 to proliferate, produce IFN-γ, and eradicate tumor cells. J Immunol. 2005;174(2):898-906.
14. Simpson-Abelson MR, Sonnenberg GF, Takita H, Yokota SJ, Conway Jr TF, Kelleher Jr RJ, et al. Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice. J Immunol. 2008;180(10):7009-18.
15. Harui A, Kiertscher SM, Roth MD. Reconstitution of huPBL-NSG mice with donor-matched dendritic cells enables antigen-specific T-cell activation. J Neuroimmune Pharmacol. 2011;6(1):148-57.
16. Engram JC, Cervasi B, Borghans JA, Klatt NR, Gordon SN, Chahroudi A, et al. Lineage-specific T-cell reconstitution following in vivo CD4+ and CD8+ lymphocyte depletion in nonhuman primates. Blood. 2010;116(5):748-58.
17. Gorantla S, Makarov E, Finke-Dwyer J, Gebhart CL, Domm W, Dewhurst S, et al. CD8+ cell depletion accelerates HIV-1 immunopathology in humanized mice. J Immunol. 2010;184(12):7082-91.
18. Kitchen SG, Korin YD, Roth MD, Landay A, Zack JA. Costimulation of naive CD8(+) lymphocytes induces CD4 expression and allows human immunodeficiency virus type 1 infection. J Virol. 1998;72(11):9054-60.
19. Ishikawa F, Yasukawa M, Lyons B, Yoshida S, Miyamoto T, Yoshimoto G, et al. Development of functional human blood and immune systems in NOD/SCID/IL2 receptor gamma chain (null) mice. Blood. 2005;106(5):1565-73.
20. Kanaji N, Tadokoro A, Susaki K, Yokokura S, Ohmichi K, Haba R, et al. Higher susceptibility of NOD/LtSz-scid Il2rg (/) NSG mice to xenotransplanted lung cancer cell lines. Cancer Manag Res. 2014;6:431-6.
21. Yu CI, Gallegos M, Marches F, Zurawski G, Ramilo O, García-Sastre A, et al. Broad influenza-specific CD8+ T-cell responses in humanized mice vaccinated with influenza virus vaccines. Blood. 2008;112(9):3671-8.
22. Bronte V, Kasic T, Gri G, Gallana K, Borsellino G, Marigo I, et al. Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers. J Exp Med. 2005;201(8):1257-68.
23. Joncker NT, Marloie MA, Chernysheva A, Lonchay C, Cuff S, Klijanienko J, et al. Antigen-independent accumulation of activated effector/memory T lymphocytes into human and murine tumors. Int J Cancer. 2006;118(5):1205-14.
24. Van den Hove LE, Van Gool SW, Van Poppel H, Baert L, Coorevits L, Van Damme B, et al. Phenotype, cytokine production and cytolytic capacity of fresh (uncultured) tumour-infiltrating T lymphocytes in human renal cell carcinoma. Clin Exp Immunol. 1997;109(3):501-9.
25. Seo AN, Lee HJ, Kim EJ, Kim HJ, Jang MH, Lee HE, et al. Tumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer. Br J Cancer. 2013;109(10):2705-13.
26. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455-65.
27. Slovin SF, Higano CS, Hamid O, Tejwani S, Harzstark A, Alumkal JJ, et al. Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study. Ann Oncol. 2013;24(7):1813-21.
28. Zippelius A, Batard P, Rubio-Godoy V, Bioley G, Liénard D, Lejeune F, et al. Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance. Cancer Res. 2004;64(8):2865-73.
29. Yu P, Fu YX. Tumor-infiltrating T lymphocytes: friends or foes? Lab Invest. 2006;86(3):231-45.
30. Kiniwa Y, Miyahara Y, Wang HY, Peng W, Peng G, Wheeler TM, et al. CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer. Clin Cancer Res. 2007;13(23):6947-58.
31. Radoja S, Frey AB. Cancer-induced defective cytotoxic T lymphocyte effector function: another mechanism how antigenic tumors escape immune-mediated killing. Mol Med. 2000;6(6):465-79.
32. Gorelik L, Flavell RA. Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells. Nat Med. 2001;7(10):1118-22.
33. Shafer-Weaver KA, Anderson MJ, Stagliano K, Malyguine A, Greenberg NM, Hurwitz AA. Cutting edge: tumor-specific CD8 T cells infiltrating prostatic tumors Are induced to become suppressor cells. J Immunol. 2009;183:4848-52.
34. Ye J, Ma C, Wang F, Hsueh EC, Toth K, Huang Y, et al. Specific recruitment of γδ regulatory T cells in human breast cancer. Cancer Res. 2013;73(20):6137-48.
35. Pfitzenmaier J, Vessella R, Higano CS, Noteboom JL, Wallace Jr D, Corey E. Elevation of cytokine levels in cachectic patients with prostate carcinoma. Cancer. 2003;97(5):1211-6.
36. Tazaki E, Shimizu N, Tanaka R, Yoshizumi M, Kamma H, Imoto S, et al. Serum cytokine profiles in patients with prostate carcinoma. Exp Ther Med. 2011;2(5):887-91.
37. Gonzalez L, Strbo N, Podack ER. Humanized mice: novel model for studying mechanisms of human immune-based therapies. Immunol Res. 2013;57(1-3):326-34.
38. Shultz LD, Goodwin N, Ishikawa F, Hosur V, Lyons BL, Greiner DL. Human cancer growth and therapy in immunodeficient mouse models. Cold Spring Harb Protoc. 2014;2014(7):694-708.
39. Wege AK, Ernst W, Eckl J, Frankenberger B, Vollmann-Zwerenz A, Männel DN, et al. Humanized tumor mice-a new model to study and manipulate the immune response in advanced cancer therapy. Int J Cancer. 2011;129(9):2194-206.
40. Kiertscher SM, Roth MD. Human CD14+ leukocytes acquire the phenotype and function of antigen-presenting dendritic cells when cultured in GM-CSF and IL-4. J Leukoc Biol. 1996;59(2):208-18.